BACKGROUND: Cancers in the proximal colon, distal colon, and rectum are frequently studied together; however, there are biological differences in cancers across these sites, particularly in the prevalence of microsatellite instability.
CONCLUSION: Proximal colon cancer survival differs from survival for distal colon and rectal cancer in a manner apparently dependent on microsatellite instability status. these findings support the premise that proximal colon, distal colon, and rectal cancers are clinicopathologically distinct.
KEy WORDS: Colorectal cancer; Colon cancer; Rectal cancer; survival; microsatellite instability. C ancers arising in sites from the proximal to distal portions of the colon are frequently studied in combination with each other (ie, colon cancer) and in combination with cancers arising in the rectum (ie, colorectal cancer). increasing evidence, however, indicates that risk factors [1] [2] [3] [4] [5] and molecular profiles [6] [7] [8] [9] of cancers may differ across these sites. for example, family history is more strongly associated with risk of proximal colon cancer than rectal cancer, 1 and alcohol consumption is more strongly associated with the risk of rectal cancer than colon cancer. 4 Cancers in the proximal colon are more likely than cancers in the distal colon and rectum to be diagnosed in women, 10, 11 to exhibit microsatellite instability (msi), [7] [8] [9] 12 and to be diagnosed at a later age. 7, [10] [11] [12] Recent studies suggest that differences in biological characteristics and risk factors across cancer sites within the colon and rectum may translate to differences in survival. in particular, proximal colon cancer has been associated with poorer survival than distal colon cancer, 10, 11, 13 but there appears to be little difference in survival for cancers arising in the distal colon versus rectum. 10 this finding is contrary to observations that proximal colon cancers are more likely to exhibit high MSI (MSI-H) and that msi-h tumors are, overall, associated with a more favorable prognosis than tumors exhibiting low or no msi (mss/msi-l). 14 two recent studies have suggested that finer distinctions in tumor localization (ie, subsite within the proximal colon, distal colon, or rectum) are informative of survival, 10, 13 although these studies have not evaluated the contribution of msi status to survival differences.
With the use of data from the Colon Cancer family Registry, we evaluated differences in all-cause mortality after colon or rectal cancer diagnosis according to tumor site, both overall and by msi status.
MATERIALS AND METHODS

Study Population
the study population included men and women diagnosed with incident invasive primary colon or rectal cancer who were enrolled in the Colon Cancer family Registry (C-CfR). the C-CfR is an international resource representing a collaboration between 6 study centers in Canada, the united states, and australia. Recruitment protocols and eligibility criteria have been described in detail elsewhere. 15 the present analysis was restricted to patients identified from population-based cancer registries and enrolled through 4 sites (fred hutchinson Cancer Research Center, seattle, Wa; mayo Clinic, Rochester, mn; Cancer Care ontario, toronto, on, Canada; and university of melbourne, melbourne, Victoria, australia). eligible patients were diagnosed between January 1997 and June 2002, with ages at diagnosis ranging from 18 to 74 years (n = 4073). a small number of patients were diagnosed with synchronous tumors at different sites (n = 36 patients with 2 tumors and n = 3 patients with 3 tumors); those patients were excluded from the present analysis. Patients completed risk factor surveys within 5 years of diagnosis including information regarding family history, demographic and anthropometric factors, medical history, smoking history, and the use of nonsteroidal antiinflammatory drugs (https://cfrisc.georgetown.edu/isc/ dd.questionnaires.do). most patients were interviewed within 2 years of diagnosis (>85%).
Vital Status
Vital status and date of death were determined via passive follow-up by routine linkage to cancer registries and national death indices. this information was also obtained through active follow-up with patients and/or relatives at, on average, 5-year intervals after study recruitment.
Tumor Subsite and MSI Assessment
tumor subsite was determined based on the review of pathology records. Proximal colon cancer was defined as cancer arising in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure (International Classification of Diseases for Oncology, Third Edition codes C180, C182, C183, C184, and C185) 16 ; cancers in the descending (C186) or sigmoid colon (C187) were classified as distal colon cancers, and cancers in the rectosigmoid junction (C199) or rectum (C209) were grouped together as rectal cancers. Patients with an unknown tumor site were excluded from the present analysis (n = 78). microsatellite instability status was evaluated for patients with available tumor tissue (n = 3284). microsatellite instability was determined via genetic analysis for most patients (n = 2969), based on a 10-marker panel (BAT25, BAT26, BAT40, MYCL, D5S346, D17S250, ACTC, D18S55, D10S197, and BAT34C4) by the use of Dna extracted from formalin-fixed, paraffin-embedded normal and tumor tissue as previously described. 17, 18 tumors were classified as msi-h if instability was observed for ≥30% of markers (n = 423), and as MSS/MSI-L if instability was observed for <30% of markers (n = 2546). for other patients (n = 315), msi was approximated based on immunohistochemistry testing of 4 markers: hMLH1, hmsh2, hmsh6, and hPms2. 18, 19 Patients who exhibited positive staining for all markers were considered MSS/ msi-l (n = 278); patients who were negative on at least 1 marker were considered MSI-H (n = 37). Thus, the study population included 2824 mss/msi-l and 460 msi-h patients. Patients with unknown MSI status were excluded (n = 630).
Statistical Analysis
We used Cox proportional hazards regression to evaluate the association between tumor location and all-cause mortality after cancer diagnosis, where the time axis was defined as days since diagnosis and death was the outcome of interest. in separate analyses, we evaluated associations with grouped tumor sites (ie, proximal colon, distal colon, rectum) and with individual tumor subsites (eg, cecum, descending colon, rectosigmoid junction). for the analysis of grouped tumor sites, we used the most common group (ie, proximal colon) as the referent category; for analyses of individual tumor subsites, we used the most common subsite within the proximal colon (ie, cecum) as the referent category.
We also conducted analyses jointly stratifying patients by tumor location and msi status (mss/msi-l, msi-h). We assessed heterogeneity by msi status in associations with tumor site by the use of likelihood ratio tests to compare models distinguishing tumors at each site by msi status with models combining tumors by site regardless of msi status.
Proportional hazards assumptions were verified by testing for a nonzero slope of the scaled schoenfeld residuals on ranked failure times. 20 Because of a violation of proportional hazards when evaluating associations across the full duration of study follow-up, follow-up was truncated at 5 years postdiagnosis; thus, all patients still alive at 5 years postdiagnosis were censored at that time.
Regression models were adjusted for age at diagnosis (10-year strata), year of diagnosis (1997-1998, 1999, 2000-2002) , sex, study site, education level (high school graduate or less, some college or vocational school, college graduate), and BMI (<25.0, 25.0-29.9, ≥30.0 kg/m 2 ); analyses not stratified by msi were adjusted for msi. We also evaluated confounding by nonsteroidal anti-inflammatory drug use (yes, no), family history of colorectal cancer in first-degree relatives (yes, no), smoking (never, former, current smoker), history of endoscopic screening at least 2 years before diagnosis (yes, no), and race (nonhispanic white, other); however, these variables did not influence estimates sufficiently to be included in the final model (<10% change). Because information on stage at diagnosis was not available for a large proportion of patients (46%, n = 1516), we did not adjust for stage in our primary analyses. We did, however, conduct sensitivity analyses assessing the impact of stage adjustment in patients with a known stage at diagnosis, and conducted sensitivity analyses adjusting for t-stage and nodal status (ie, the t and n components of tnm stage) which were known for a larger proportion of patients (84%, n = 2757). Because hereditary nonpolyposis colorectal cancer (hnPCC) may be associated with a better prognosis than sporadic disease, 21 and because HNPCC is more likely to be msi-h and proximally located than sporadic disease, we also conducted sensitivity analyses excluding patients with germline mutations in 1 of 4 Dna mismatch repair genes (MLH1, MSH2, MSH6, and PMS2), which could reflect hnPCC. all analyses were conducted by the use of stata se version 11.0 (College station, tX).
RESULTS
after a median follow-up of 6.7 years (range, 0.7-14.5 years), approximately 35% of enrolled patients were no longer alive (n = 1144); of those who died, 66% died in the first 5 years after diagnosis (n = 754) (table 1). in comparison with patients who were alive at the end of follow-up or at 5 years postdiagnosis (whichever came first), patients who died within 5 years of diagnosis were more likely to be male (58% vs 51%), more likely to have ever been a smoker (64% vs 59%), more likely to have poorly differentiated tumors (26% vs 16%), and less likely to have MSI-H tumors (8% vs 16%) (p values all <0.05).
Patients with proximal colon cancer accounted for 38% of the study population; distal colon and rectal cancers accounted for 28% and 34% of patients (table 2) . the distribution of cancer subsite was similar for women and men, with the exception that women had a greater proportion of cancers located in the cecum (18% vs 13%) and a lower proportion of cancers located in the rectum (20% vs 27%). the distribution of tumor site differed by msi status: 82% of msi-h tumors were located in the proximal colon, compared with 31% of mss/msi-l tumors. tumors in individuals with germline mismatch repair mutations (n = 70) were also more likely to be located in the proximal colon (71% vs 37% in other patients, not shown).
overall, patients who had distal colon cancer and rectal cancer experienced significantly lower mortality than patients with proximal colon cancer (table 3) . however, there was evidence of interaction in this association with tumor site by msi status (p interaction = 0.04 and 0.15 for distal colon and rectal cancer). in comparison with patients who had mss/msi-l proximal colon cancer, patients with msi-h cancer had lower mortality regardless of grouped tumor site ( fig. 1 ); patients with mss/msi-l distal colon or mss/msi-l rectal cancer also had significantly lower mortality than patients with mss/ msi-l proximal colon cancer. in comparison with patients who had msi-h proximal colon cancer, all mss/msi-l patient groups experienced significantly higher mortality, regardless of grouped tumor site. Very few patients with msi-h had distal colon or rectal cancer, but patterns of association for these patient groups were the same as for mss/msi-l distal colon and rectal cancer patient groups. microsatellite instability status was not associated with all-cause mortality for patients with distal colon or rectal cancer (hR, 0.90; 95% Ci, 0.44-1.86 vs hR, 0.72; 95% Ci, 0.32-1.63 for msi-h vs mss/msi-l in patients with distal colon and rectal cancer, not shown). additional adjustment for stage, or for components of tnm stage, had little effect on point estimates; all statistically significant findings remained significant with stage adjustment (results not shown). the exclusion of patients with germline mismatch repair mutations also had no impact on findings.
Based on observed differences in associations with tumor site by msi status, analyses of all-cause mortality by individual tumor subsites were stratified by msi. among mss/msi-l patients, those who had cancer located within the descending colon, sigmoid colon, rectosigmoid junction, and rectum experienced significantly lower mortality than patients with cecal cancer (table 4). there was no difference in associations across individual subsites within the distal colon (p heterogeneity = 0.73) or rectum (p heterogeneity = 0.81). among patients with mss/msi-l proximal colon cancer, those who had cancer located in the hepatic flexure experienced significantly lower mortality than individuals with cancer in the cecum (hR, 0.50; 95% Ci, 0.26-0.95), but mortality was otherwise similar across proximal colon subsites (p heterogeneity = 0.14). Results were unchanged when adjusting for stage and when excluding patients with germline mismatch repair mutations (not shown). small numbers limited analyses by tumor subsite for msi-h patients; however, patients who had msi-h sigmoid colon cancer were found to have significantly higher mortality relative to patients who had msi-h cecal cancer (hR, 2.64; 95% Ci, 1.00-6.96). When we analyzed the 8 subsites from cecum to rectum as a continuous variable, there was a significant association between increasing distance from the cecum and lower mortality (hR, 0.93; 95% Ci, 0.90-0.95), with evidence of interaction by msi status (p = 0.009) (not shown).
DISCUSSION
in this cohort of individuals with invasive colon or rectal cancer, we found that those with tumors in the distal colon and rectum experienced lower all-cause mortality in the 5 years after diagnosis relative to individuals with proximal colon cancer. however, comparisons of mortality by tumor site differed by msi status: mss/msi-l proximal colon cancer was associated with the poorest prognosis, whereas msi-h proximal colon cancer was associated with the best prognosis. We found little difference in these patterns when more finely evaluating associations across subsites within the proximal colon, distal colon, and rectum.
Certain limitations should be considered in interpreting these findings. in particular, inclusion in the study population was contingent on surviving long enough after cancer diagnosis to be enrolled in the C-CfR. selection bias is possible if otherwise eligible patients who died before they could be enrolled differed from included patients with respect to tumor location or covariates. additionally, we were unable to evaluate treatment variables as con- founders or effect modifiers because we did not have this information; however, it is unlikely that treatment or access to treatment differed substantially by tumor location. similarly, we did not adjust for stage at diagnosis because this information was not available for a large fraction of patients; we were also concerned that stage classification and the assessment of stage components could differ across tumor subsites, in which case, stage adjustment could create difficulties for interpretation. We did, however, conduct sensitivity analyses adjusting for components of stage and for stage in the subset of patients with known stage and found that any confounding by stage was not responsible for observed survival differences. although we had a large study population, some patient groups became small after stratification by msi status and tumor site. specifically, as has been reported by previous studies, 7, 9, 12 we had few patients who had msi-h distal colon cancer or msi-h rectal cancer; thus, interpretation of comparisons with these small patient groups should be made cautiously. last, although the vast majority of patients (75%) were followed up beyond 5 years postdiagnosis, we truncated follow-up at 5 years in this analysis to avoid violations of proportional hazards assumptions. as a result, patients who died more than 5 years postdiagnosis were censored before they experienced the study outcome. however, by truncating follow-up, it also became much more likely that patients who died during the period of analysis died as a result of their disease and not because of some other cause. although we did not have cause-of-death information for most patients, within the subset of patients for whom we did have cause of death data (41%), approximately 80% of deaths occurring within the first 5 years postdiagnosis were attributable to colon or rectal cancer, compared with only 41% of deaths occurring more than 5 years postdiagnosis (not shown). Consistent with our results, most previous studies have suggested that proximal colon cancers are associated with greater mortality than distal colon 7, 10, 11, 13 and rectal cancers. 10 Recently, a study from the swedish family-Cancer Database demonstrated significantly greater causespecific mortality in patients diagnosed with proximal colon cancer relative to patients with rectal cancer (hR, 1.16; 95% Ci, 1.07-1.27), but found no difference in survival between patients with distal colon versus rectal cancer (hR, 1.04; 95% Ci, 0.95-1.15). 10 in another analysis, Wray et al 13 found lower all-cause mortality in patients diagnosed with cancer located in the sigmoid colon than in those with cancer located in the cecum, ascending colon, or hepatic flexure (hR, 0.90; 95% Ci, 0.87-0.92).
Previous observations that proximal colon cancer is associated with poorer survival than distal colon or rectal cancer 7, 10, 11, 13 appear inconsistent with observations that proximal colon cancers are more likely to be MSI-H, 7, 9, 12 because msi-h cancers generally have a more favorable prognosis than mss/msi-l cancers. 14 We found that the greater mortality associated with a proximal colon tumor location was restricted to mss/msi-l proximal colon cancer, and that the more favorable survival associated with msi-h status was limited to proximal colon cancer. Very few previous studies considered msi in evaluating survival differences by tumor site or, conversely, considered tumor site in evaluating associations by msi. 12, 22, 23 one study by Jernvall et al 22 reported that the survival advantage associated with msi-h status was limited to patients with proximal colon cancer. another analysis of patients enrolled in clinical trials demonstrated greater mortality in patients with distal colon cancer relative to patients with proximal colon cancer, and found this association to be diminished after excluding msi-h patients. 12 these studies support our finding that the interaction between msi and tumor location is of critical importance in evaluating survival differences by msi status or tumor location. however, given the rarity of the msi-h phenotype in distal colon and rectal cancers in these previous studies 12, 21, 23 and in ours, there remains a need to better understand the epidemiological and clinical profile of msi-h distal colon and rectal cancers.
it is possible that differences in all-cause mortality by tumor site reflect underlying differences in tumor aggressiveness or amenability to screening. Consistent with such a hypothesis, previous studies have found that sigmoidoscopy 24, 25 and colonoscopy 26, 27 are associated with lower incidence and mortality for distal but not proximal colon cancer. Proximal colon cancers are more likely to be diagnosed as interval cancers, 28, 29 which could imply a more rapid pattern of tumor progression, and are also more likely to be BRAF mutated and to exhibit a CpG island methylator phenotype 9 ; these characteristics, when observed in combination with mss/msi-l status, have been associated with poorer prognosis. 30, 31 We did not have information on BRAF mutation or CpG island methylator phenotype status, but found that cancers at all sites within the proximal colon were more likely to be poorly differentiated than cancers at sites within the distal colon or rectum (results not shown). Differences in the distribution of msi status for proximal colon cancer versus distal colon and rectal cancer may also be indicative of differences in pathways of tumor development. Previous studies have hypothesized that msi-h status reflects a pathway(s) of tumor development distinct from mss/ msi-l tumors, as reflected by differences in the prevalence of certain somatic mutations and epigenetic alterations 32 ; these differences, in turn, may have an important impact on survival.
CONCLUSIONS
all-cause mortality after diagnosis of colon or rectal cancer differed significantly for patients with tumors located in the proximal colon relative to patients with distal colon or rectal cancer. for individuals with proximal colon cancer, mortality risk differed significantly according to msi status. mss/msi-l proximal colon cancer was associated with a greater mortality than msi-h proximal colon cancer and was also associated with greater mortality than mss/msi-l or msi-h distal colon or rectal cancers. Conversely, msi-h proximal colon cancers were associated with the most favorable survival. these findings are consonant with a more aggressive clinicopathology of mss/ msi-l tumors located in the proximal colon.
